Executive Summary
SGLT2 inhibition after TAVI now has its cleanest efficacy signal across the LVEF spectrum: DapaTAVI's pre-specified LVEF analysis in EJHF shows dapagliflozin cuts death or worsening heart failure at one year regardless of baseline ejection fraction (interaction P=0.41 across 1,223 patients), which tightens the case for treating post-TAVI patients as a heart-failure population rather than a valve-corrected one. Meanwhile, the first multicenter JenaValve Trilogy registry in LVAD-associated pure AR reports 93.3% VARC-3 device success in 30 patients — the first credible transcatheter answer to a population the ESC 2025 guideline still leaves in a Class IIb gray zone. On the mitral side, a federal kickbacks lawsuit against Abbott's MitraClip program will proceed, adding legal risk to a device the ESC just upgraded to Class I.
- DapaTAVI's LVEF-stratified analysis extends SGLT2i benefit to the full ejection fraction range in post-TAVI patients (N=1,223), with genitourinary infection the only safety trade-off (EJHF).
- JenaValve Trilogy achieved 93.3% device success and 3.3% 30-day mortality across five centers in LVAD patients with pure AR — a niche with no surgical alternative (Artificial Organs).
- A new TAVR-PRO score (age ≥80, CFS >4, NT-proBNP >3000, CAD, CKD) predicted poor 6-month functional recovery with AUC 0.88 in 204 patients (Clin Interv Aging).
- LuX-Valve TTVR at three Chinese centers delivered 88.8% survival at mean 46 months with 22.6% 30-day MAE — mid-term TTVR data remain scarce (TRAVEL).
- HighLife received CE Mark for its next-generation Clarity valve within the HighLife TMVR system, adding another dedicated TMVR device to the European pipeline (Manila Times).
What to watch: Medtronic reports fiscal Q1 earnings September 1 — structural heart segment commentary on TAVR share versus Edwards will set the tone heading into TCT.
Aortic Valve (TAVR/TAVI)
The most important aortic finding today isn't about the valve — it's about what you do after you deploy it. DapaTAVI's LVEF-stratified analysis in EJHF confirms dapagliflozin reduces death or worsening HF at one year across the full ejection fraction spectrum (20.2% event rate in LVEF ≤40% vs 17.0% in LVEF >40%; no interaction). The mechanism, per the accompanying SGLT2i-in-VHD review, is cardiorenal and HF protection, not valve modification. Neither ACC/AHA 2020 nor ESC 2025 addresses post-TAVI SGLT2i as guideline-directed therapy — this data moves that conversation from hypothesis to clinical imperative. [NOTABLE] The TAVR-PRO score (age ≥80, CFS >4, NT-proBNP >3000 pg/mL, CAD, CKD; AUC 0.88 training / 0.86 validation, single-center N=204) is a pragmatic frailty-first tool that outperforms comorbidity aggregation — reinforced by a separate analysis showing EuroSCORE II and CCI barely discriminate 30-day VARC-3 events (AUCs 0.50–0.54). On leaflet thrombosis, a Vietnamese two-center MDCT cohort found HALT in 30.8% at 1–3 months, with severe RCA ostial eccentricity plus neo-sinus–RCA distance >13 mm independently associated (adjusted OR 5.52) — exploratory given only 20 events, but consistent with the neo-sinus washout hypothesis reviewed in Interventional Cardiology Clinics. ACC/AHA 2020 still favors SAVR below age 65, and ESC 2025 below age 70 in low-risk patients. Today's data does nothing to change that — the durability question for TAVR under age 70 remains unanswered by any trial published today.
Mitral Valve (MitraClip, PASCAL, TMVR)
MitraClip's Class I ESC 2025 upgrade now runs alongside meaningful legal exposure. A federal court will allow a whistleblower kickbacks case against Abbott's MitraClip program to proceed — the merits will play out, but discovery alone will scrutinize marketing and physician-relationship practices during exactly the period ESC-driven volume expansion is projected. Surgical repair remains the dominant Class I answer for primary MR under both ACC/AHA 2020 and ESC 2025, and continues to outperform any transcatheter alternative on durability. On the transcatheter mitral pipeline, HighLife's CE Mark for the Clarity Valve gives the HighLife TMVR system its next-gen device in Europe — one more entrant into a category where transapical delivery and paravalvular sealing remain the discriminating engineering problems. Neither guideline endorses TMVR outside of valve-in-valve or MAC indications (ESC 2025 Class IIb for degenerative MS with MAC).
Tricuspid Valve (TriClip, TTVR)
Mid-term TTVR data remain scarce, and the TRAVEL study of the LuX-Valve at three Chinese centers (N=62, mean follow-up 46 months) is a useful addition: 88.8% mid-term survival, 30-day MAE 22.6% (major bleeding 12.9%, surgical re-exploration 11.3%, pacemaker 9.7%), TR reduced to mild or less in 95.2% at one year. LuX-Valve is a transatrial device — this is not a percutaneous transfemoral experience — and the retrospective single-arm design plus small sample limit inference. ESC 2025 rates transcatheter TV treatment Class IIa (LOE A) on the strength of TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II; ACC/AHA 2020 offers no recommendation. Surgical counterpoint: ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I, and the too-late-referral problem is real — historical isolated TV surgery mortality of 8–20% is falling in contemporary earlier-referral cohorts. The robotic TTVR simulation platform published today is a pre-clinical training scaffold, not a clinical result.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. The day's transcatheter findings sit against a surgical comparator that hasn't moved: SAVR remains Class I below age 65 (ACC/AHA) and below age 70 (ESC) in low-risk patients, mitral repair remains preferred over TEER for primary MR, and surgical TV repair or replacement remains Class I for severe primary TR in operable patients under ESC 2025. What today's data shifts is the peri-procedural conversation — post-TAVI SGLT2i, better frailty-based patient selection, and a dedicated device (JenaValve Trilogy) for a niche (LVAD-associated pure AR) where surgery is prohibitive.
Device & Technology
The JenaValve Trilogy multicenter LVAD-AR registry (N=30, five centers, Germany/US) is the first meaningful evidence base for transcatheter treatment of a mechanistically distinct disease: LVAD-induced pure AR without annular calcification. Device success 93.3%, 30-day mortality 3.3%, median follow-up survival 93.3% at 273 days. A separate single-center Turkish series (N=14) used balloon-expandable valves off-label for the same indication with area-based oversizing of 15–30%, achieving VARC-3 device success in 71.4% with 28.6% requiring a second valve — a stark contrast that argues for dedicated AR devices over improvised balloon-expandable use. The Interventional Cardiology Clinics review on TAVR for native AR reinforces this framing. Trilogy remains the only transfemoral device with regulatory approval for AR. ESC 2025 rates TAVI for AR Class IIb for inoperable patients with suitable anatomy; surgical aortic valve replacement remains the default for operable candidates under both guidelines.
Regulatory & Policy
The FDA elevated Boston Scientific's ENROUTE Transcarotid Neuroprotection System recall to the most serious category following reports of arterial sheath tip separation — one serious injury, no deaths reported. This is a carotid stenting device, not structural heart, but it lives in the same interventional inventory ecosystem and one serious injury behind a Class I recall is instructive for how the agency is triaging embolic protection technology. HighLife's CE Mark for the Clarity Valve adds a European approval to the TMVR pipeline without a corresponding FDA pathway announcement.
Industry & Market
The Abbott MitraClip kickbacks lawsuit clearing its motion to dismiss is the industry story of the day. Discovery in kickback cases routinely surfaces internal marketing communications, physician payment records, and volume-target documents — material that will be assessed against the backdrop of the ESC 2025 Class I upgrade for TEER in ventricular SMR. The market has not yet priced this; Abbott closed down 1.75%. Boston Scientific's 3.4% single-day drop and 37% six-month decline are dominated by non-structural-heart concerns but coincide with today's ENROUTE recall.
Financial Analysis
Edwards Lifesciences saw a cluster of institutional filings today — Jupiter Topco's new $112.19M position, Man Group adding 935,186 shares, and new stakes from CDPQ, CIBC, Legal & General, Manufacturers Life, and Primecap. Simultaneously, two executives sold: CVP Daveen Chopra ($2.9M) and CVP Wayne Markowitz. The clinical context: DapaTAVI reinforces the durability of the TAVI patient population that Edwards' SAPIEN franchise dominates, and the JenaValve Trilogy AR expansion sits alongside Edwards' own AR pipeline aspirations. Institutional buying is consistent with a thesis that structural heart TAM is expanding faster than incremental competition.
Valve Industry Stocks
Edwards Lifesciences (EW)
Closed $90.78, down 0.10% on the day, up 4.98% over six months. Market cap $52.3B, trailing P/E 54.04, forward P/E 26.88, beta 0.85. 52-week range $72.30–$96.29. Analyst consensus target $100.96 (26 analysts, buy). Q3 2026 earnings October 29 (EPS est $0.74, revenue est $1.68B). Heavy institutional accumulation today alongside insider selling; the setup is neutral into TCT, where PARTNER long-term durability and TRISCEND II follow-up will dominate the SAPIEN and EVOQUE narratives.
Medtronic (MDT)
Closed $92.02, up 0.97%, down 4.15% over six months. Market cap $117.8B, trailing P/E 24.67, forward P/E 14.37, beta 0.57. 52-week range $73.31–$106.33. Consensus target $97.92 (25 analysts, buy). Fiscal Q1 earnings September 1 (EPS est $1.39, revenue est $9.54B). Evolut FX structural heart commentary is the key readout; the self-expanding platform review in Interventional Cardiology Clinics today reinforces the small-annulus and hemodynamics case.
Abbott Laboratories (ABT)
Closed $114.10, down 1.75%, essentially flat over six months. Market cap $198.7B, trailing P/E 36.93, forward P/E 18.81, beta 0.58. 52-week range $81.97–$137.49. Consensus target $120.20 (25 analysts, buy). Q3 2026 earnings October 14 (EPS est $1.42, revenue est $12.99B). Today's drop lines up with the MitraClip kickbacks case surviving dismissal; discovery risk is real but MitraClip revenue exposure is a low-single-digit percentage of total. Watch for structural heart guidance commentary.
Boston Scientific (BSX)
Closed $48.17, down 3.39%, down 37.32% over six months. Market cap $69.8B, trailing P/E 20.24, forward P/E 14.03, beta 0.57. 52-week range $42.20–$109.50. Consensus target $62.69 (29 analysts, buy). Q3 earnings October 28 (EPS est $0.81, revenue est $5.26B). The ENROUTE Class I recall today compounds an already brutal six-month drawdown. ACURATE neo2 momentum and WATCHMAN volumes are the structural offset.
Anteris Technologies (AVR.AX)
Closed AUD $12.17, down 0.65%, up 38.30% over six months. Market cap AUD $1.2B, forward P/E negative reflecting pre-commercial stage. DurAVR THV clinical pipeline is the story; single-analyst coverage limits consensus signal.
Private structural heart players — JenaValve Technology (today's Trilogy multicenter data), J Valve Technology, Meril Life Sciences, and HighLife (CE Mark for Clarity today) — remain outside public equity coverage but continue to compress the TAM opportunity for the majors, particularly in AR and TMVR.
Market outlook: the majors are trading on macro and idiosyncratic litigation/recall risk more than on structural heart fundamentals. The clinical evidence base for TAVI expansion (DapaTAVI, TAVR-PRO) and AR/TMVR/TTVR pipeline maturation continues to build. Sector volume growth remains the durable thesis.
Clinical Trial Updates
DapaTAVI's LVEF-stratified secondary analysis (39 Spanish centers, N=1,223, pragmatic open-label with blinded endpoint adjudication) is the most consequential trial-level update today. The JenaValve Trilogy LVAD-AR multicenter registry and the TRAVEL LuX-Valve TTVR study are both retrospective, single-arm, and small — hypothesis-generating, not practice-changing on their own.
Social & Conference Highlights
Quiet news day ahead of TCT 2026. The TAVR-PRO score coverage is the finding most likely to enter clinical conversation this week.
Next up: Medtronic earnings September 1 opens the fall structural heart cycle, followed by TCT, where five-year and ten-year TAVI durability, TRISCEND II follow-up, and post-TAVI medical therapy will define what the next ACC/AHA update inherits from ESC 2025.